CoChat

A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates

Open access
Wang, Dan, Li, Shaoyong, Gessler, Dominic J., Xie, Jun, Zhong, Li, Li, Jia, Tran, Karen, Van Vliet, Kim, Ren, Lingzhi, Su, Qin, He, Ran, Goetzmann, Jason E., Flotte, Terence R., Agbandje-McKenna, Mavis, Gao, Guangping · 2018 · Molecular Therapy - Methods & Clinical Development
Cited by 73

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

gene delivery vector to realize safe, efficacious, and sustainable therapeutic gene expression. Because many clinically relevant properties of AAV-based vectors are governed by the capsid, much research effort has been devoted to the development of AAV capsids for desired features. Here, we combine AAV capsid discovery from nature and rational engineering to report an AAV9 capsid variant, designated as AAV9.HR, which retains AAV9's capability to traverse the blood-brain barrier and transduce neurons. This variant shows reduced transduction in peripheral tissues when delivered through intravascular (IV) injection into neonatal mice. Therefore, when IV AAV delivery is used to treat CNS diseases, AAV9.HR has the advantage of mitigating potential off-target effects in peripheral tissues compared to AAV9. We also demonstrate that AAV9.HR is suitable for peripheral tissue-detargeted CNS-directed gene therapy in a mouse model of a fatal pediatric leukodystrophy. In light of recent success with profiling diversified natural AAV capsid repertoires and the understanding of AAV capsid sequence-structure-function relationship, such a combinatory approach to AAV capsid development is expected to further improve vector targeting and expand the vector toolbox for therapeutic gene delivery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2018.03.004

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 73

Metadata

Authors
Wang, D., Li, S., Gessler, D. J., Xie, J., Zhong, L., Li, J., Tran, K., Van Vliet, K., Ren, L., Su, Q., He, R., Goetzmann, J. E., Flotte, T. R., Agbandje-McKenna, M., & Gao, G.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2018-06
Volume
9
Pages
234-246
ISSN
2329-0501 (ISSN-L)
OpenAlex
W2793963983
Cited by
73
References
13
FWCI
3.33
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. https://app.cochat.ai/papers/10.1016/j.omtm.2018.03.004
The paper
Wang, D., Li, S., Gessler, D. J., Xie, J., Zhong, L., Li, J., Tran, K., Van Vliet, K., Ren, L., Su, Q., He, R., Goetzmann, J. E., Flotte, T. R., Agbandje-McKenna, M., & Gao, G. (2018). A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2018.03.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.